OGN

Organon & Co
$13.75-$0.06-0.47%Price as of Oct 30, 2026, 9:11 AM ET

Key stats

Market cap
3.61B
Open
—
Day range
—
52-week range
$5.69 – $13.83
Volume
478
Avg volume
2.27M

Earnings

Q3 FY26Upcoming
Expected$0.94
Q2 FY26
Actual$0.40
Q1 FY26
Actual$0.55
Q4 FY25
Actual$-0.78

Next earnings call Feb 11, 2027

About

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

Employees
10,000
Headquarters
Jersey City, NJ